<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062270</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000304674</org_study_id>
    <secondary_id>UAB-0162</secondary_id>
    <secondary_id>UAB-F020730006</secondary_id>
    <secondary_id>ZENECA-ZD1839US-0207</secondary_id>
    <secondary_id>AVENTIS-GIA-12139</secondary_id>
    <nct_id>NCT00062270</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer</brief_title>
  <official_title>Neoadjuvant Chemoradiotherapy (Gemcitabine/Cisplatin and Taxotere) With or Without Co-Administration of ZD 1839 (Iressa) for Stage IIIA (N2) and Selective Stage IIIB Non-Small Cell Lung Cancer: Phase I-II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Biological therapies such as gefitinib may interfere with the growth of the tumor cells and&#xD;
      slow the growth of the tumor. Combining chemotherapy and radiation therapy with gefitinib&#xD;
      before surgery may shrink the tumor so that it can be removed during surgery.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to compare the effectiveness of neoadjuvant chemoradiotherapy with&#xD;
      or without gefitinib in treating patients who are undergoing surgery for stage III non-small&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Phase I:&#xD;
&#xD;
        -  Determine the tolerability and toxicity of gefitinib in combination with chest&#xD;
           radiotherapy in patients with stage IIIA or stage IIIB non-small cell lung cancer.&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
        -  Compare the pathologic response (complete response and rate of downstaging) in patients&#xD;
           treated with neoadjuvant chemoradiotherapy with vs without gefitinib.&#xD;
&#xD;
        -  Compare the feasibility and toxicity profile of these regimens in these patients.&#xD;
&#xD;
        -  Compare the resection rates, time to progression, and overall survival of patients&#xD;
           treated with these regimens.&#xD;
&#xD;
        -  Correlate the percent decline in the fludeoxyglucose F 18 standardized uptake value as&#xD;
           measured by position emission tomography with pathologic response at resection, time to&#xD;
           progression, and overall survival in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Phase I: This is an open-label, nonrandomized study.&#xD;
&#xD;
             -  Induction: Patients receive cisplatin IV over 60 minutes on day 1 and gemcitabine&#xD;
                IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for a total of&#xD;
                2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Consolidation: Within 3-4 weeks after the completion of induction therapy, patients&#xD;
                undergo radiotherapy once daily 5 days a week for 5 weeks and receive oral&#xD;
                gefitinib once daily concurrently.&#xD;
&#xD;
      A cohort of 3-6 patients receives consolidation chemoradiotherapy. If 2 of 6 patients&#xD;
      experience dose-limiting toxicity, gefitinib is deleted from consolidation therapy in phase&#xD;
      II arm II.&#xD;
&#xD;
        -  Surgery: Patients without disease progression after consolidation therapy undergo&#xD;
           thoracotomy within 3-5 weeks after consolidation.&#xD;
&#xD;
        -  Maintenance: Beginning 2-4 weeks after surgery, patients receive oral gefitinib once&#xD;
           daily for 6 months in the absence of disease progression.&#xD;
&#xD;
             -  Phase II: This is a randomized study. Patients are randomized to 1 of 2 treatment&#xD;
                arms.&#xD;
&#xD;
        -  Arm I: Patients receive induction and consolidation therapy (with the exception of&#xD;
           gefitinib) as in phase I. Patients also receive docetaxel IV over 60 minutes&#xD;
           concurrently with radiotherapy during consolidation. Patients undergo surgery as in&#xD;
           phase I.&#xD;
&#xD;
        -  Arm II: Patients receive therapy (including gefitinib) as in phase I. Patients also&#xD;
           receive docetaxel IV over 60 minutes concurrently with radiotherapy during&#xD;
           consolidation.&#xD;
&#xD;
      Patients are followed every 6-8 weeks for the first 12 months and then every 4-6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 43-80 patients (3-6 patients for phase I and 40-74 patients&#xD;
      [20-37 per treatment arm] for phase II) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the tolerability and toxicity of gefitinib in combination with chest radiotherapy in patients with stage IIIA or stage IIIB non-small cell lung cancer.</measure>
  </primary_outcome>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Stage IIIA (T1-3, N2)&#xD;
&#xD;
                    -  Positive (pathological) ipsilateral mediastinal node&#xD;
&#xD;
               -  Selective stage IIIB meeting all of the following criteria:&#xD;
&#xD;
                    -  No pleural/pericardial effusion or superior vena cava syndrome&#xD;
&#xD;
                    -  T4 due to invasion of carina, trachea, or mediastinal structures&#xD;
&#xD;
                    -  Mediastinal N3 nodes (without supraclavicular or cervical adenopathy)&#xD;
&#xD;
          -  Proof of N2 or N3 status requires surgical staging of the mediastinum&#xD;
             (mediastinoscopy, mediastinotomy, or exploration)&#xD;
&#xD;
          -  Expression of epidermal growth factor receptor (at least 1+) by immunohistochemistry&#xD;
&#xD;
          -  Measurable disease by contrast CT scan allowed&#xD;
&#xD;
          -  No bronchoalveolar cell carcinoma&#xD;
&#xD;
          -  No prior diagnosis of lung cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  19 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1 (0-2 if albumin is at least 0.85 times lower limit of normal and weight loss&#xD;
             within 3 months before diagnosis is no greater than 10%)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 150,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN&#xD;
&#xD;
               -  Alkaline phosphatase between 1.5-2 times ULN requires a negative bone scan for&#xD;
                  metastatic bone disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.4 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiac&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No active angina&#xD;
&#xD;
          -  No unstable heart rhythms&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Post-resection predicted FEV_1% greater than 35%&#xD;
&#xD;
               -  Predicted FEV_1% is defined as FEV_1% times percent perfusion to uninvolved lung&#xD;
                  from quantitative lung V/Q scan report&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 weeks&#xD;
             after study treatment&#xD;
&#xD;
          -  No other uncontrolled medical illness&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No concurrent ocular inflammation or infection&#xD;
&#xD;
          -  No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with&#xD;
             polysorbate 80&#xD;
&#xD;
          -  No known severe hypersensitivity reaction to gefitinib or any of its excipients&#xD;
&#xD;
          -  No prior severe allergic reaction to platinum-containing compounds or mannitol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent growth factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])&#xD;
             during chemotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for lung cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for lung cancer&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior major surgery&#xD;
&#xD;
          -  No concurrent ophthalmic surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior unapproved or investigational drugs&#xD;
&#xD;
          -  No concurrent use of the following drugs:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Hypericum perforatum (St. John's Wort)&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
          -  No concurrent retinoids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Robert, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

